MY126358A - Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs - Google Patents

Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Info

Publication number
MY126358A
MY126358A MYPI97001186A MYPI9701186A MY126358A MY 126358 A MY126358 A MY 126358A MY PI97001186 A MYPI97001186 A MY PI97001186A MY PI9701186 A MYPI9701186 A MY PI9701186A MY 126358 A MY126358 A MY 126358A
Authority
MY
Malaysia
Prior art keywords
tpgs
vitamin
compositions
water soluble
tocopherol derivative
Prior art date
Application number
MYPI97001186A
Inventor
Arup K Roy
Lloyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY126358A publication Critical patent/MY126358A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PHARMACEUTICAL FORMULATIONS CONTAINING HIV PROTEASE INHIBITORS, SPECIFICALLY INCLUDING 3S-[3R*(1R*,2S*)]-[[(4-AMINOPHENYL ](2-METHYLPROPYL)-AMINO]-2-HYDROXY-1-PHENYLMETHYL)PROPYL]CARBAMIC ACID, TETRAHYDRO-3-FURANYL ESTER (ALTERNATIVELY KNOWN AS VX 478 OR 141W94), AND A TOCOPHERAL, AND THEIR USE IN MEDICAL THERAPY ARE DESCRIBED.
MYPI97001186A 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs MY126358A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MY126358A true MY126358A (en) 2006-09-29

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97001186A MY126358A (en) 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2002051414A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006518380A (en) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション Solid dispersion composition
ATE533473T1 (en) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma NEW CLASS OF SURFUCT-LIKE MATERIALS WITH VITAMIN E-TPGS AND WATER SOLUBLE POLYMER
JP2008514714A (en) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー Pharmaceutical formulations containing vitamin ETPGS molecules solubilizing lipophilic drugs that do not exhibit significant spill inhibition and the use of such pharmaceutical formulations
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1677092A (en) * 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
DK0541168T3 (en) * 1991-11-08 1998-05-11 Merck & Co Inc HIV protease inhibitors suitable for the treatment of AIDS
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DK0727419T3 (en) * 1992-12-29 2002-06-10 Abbott Lab Intermediates for the preparation of compounds that inhibit retroviral protease
US5714518A (en) * 1993-01-15 1998-02-03 Agouron Pharmaceuticals HIV protease inhibitors and methods of making the same
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
DE69430385T2 (en) * 1993-12-15 2002-11-07 Merck & Co., Inc. HIV Protease Inhibitors
DE69512220T2 (en) * 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
HUP9901887A3 (en) 2000-02-28
OA10880A (en) 2001-10-11
HUP9901887A2 (en) 1999-12-28
IL126185A (en) 2003-05-29
BG102838A (en) 1999-09-30
BG64457B1 (en) 2005-03-31
ID16781A (en) 1997-11-13
PL328916A1 (en) 1999-03-01
CO4790151A1 (en) 1999-05-31
AR006345A1 (en) 1999-08-25
IL126185A0 (en) 1999-05-09
TW455491B (en) 2001-09-21
WO1997035587A1 (en) 1997-10-02
PL187919B1 (en) 2004-11-30
JP2000500504A (en) 2000-01-18
JP3117726B2 (en) 2000-12-18
HU228026B1 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
PT762896E (en) TOCOFEROL COMPOSITIONS FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE AGENTS
ATE533472T1 (en) LIQUID CANNABINOID FORMULATIONS FOR ADMINISTRATION TO THE MUCOUS MEASURES
HK1012566A1 (en) Pharmaceutical formulations in form of thixotropic gel
ECSP034883A (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
IL114193A0 (en) Ophthalmic pharmaceutical compositions
PA8575701A1 (en) ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY
MXPA05002814A (en) Formulation for lipophilic agents.
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
TR200001977T2 (en) Compositions containing lipophilic glucocorticosteroid micelles
WO2001038303A3 (en) Vitamin d analogues
HUP0100539A2 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
BR0304298A (en) Composition containing a cosmetically active organic acid and a vegetable product
HUP0004375A2 (en) Composition containing azelaic acid
CA2392168A1 (en) Vitamin d analogues
CA2028629A1 (en) Antiandrogenically-effective pharmaceutical compositions
HUP0304077A2 (en) Pharmaceutical and cosmetic compositions against skin aging
UA10208A (en) Dermatological cosmetic preparation
PA8449301A1 (en) PHARMACEUTICAL COMPOSITIONS
CO4970832A1 (en) NEW FORMULATIONS AND PROCESSES FOR ITS MANUFACTURE
EP1429723A4 (en) Treating effects of excessive reactive oxygen species
ATE201137T1 (en) SEMI-SOLID PHARMACEUTICAL PREPARATIONS CONTAINING DEXKETOPROFEN-TROMETAMOLE
CA2249336A1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
AU3739500A (en) Protease resistant flint analogs